

Inspire Therapeutic Design with Generative AI

Driven by Unprecedented Scale of Proprietary Data Generation

2024.11.14

Weian Zhao, Ph.D., CEO



weianzhao@aurekabin.com

<https://aurekabin.com/>

About Aureka Bio

Platform

Unprecedented protein/biologics discovery efficiency through integrated AI and high-throughput biology



Traction

- Launched in May 2023; Headquartered in Irvine, CA
- 20+ FTE of interdisciplinary team
- Established partnerships with large pharma (5), biotech (5), venture group (1)
- Member of NVIDIA Inception and MedTech/Biotech innovator accelerator programs

Financing

- Raised Seed \$8M and pre-A \$8M for developing platform and supporting partnerships
- **Current offering:** \$40M Series A to drive three internal pipelines in I&I to IND ready, with an expected 50X return in three years

Experienced, interdisciplinary, founder-led team

Leadership



Weian Zhao, PhD, CEO

- Expert in therapeutic discovery
- Immunotherapeutics FDA IND approval
- Tenured full professor, UC Irvine
- Serial entrepreneur
- MIT TR35, NIH Director's Innovator



Shuangjia Zheng, PhD, VP of AI

- Expert in AI and therapeutics design
- Former founding member and VP at top-tier AIDD company, Forbes U30
- Visiting Scientist at MIT and Harvard



Alon Wellner, PhD, VP of Biology

- Expert in synthetic biology and protein and antibody engineering
- Former senior scientist UCI
- Former head of R&D at Forrest Inno Inc.



Jacques Bouchy, Business Executive

- Ex-EVP, Kineta, GSK, Merck
- 30+ years of experience in business development, commercialization and marketing in biopharmaceutical industry



Bill Guerry, Fraction CFO

- 25+ years of experience in strategic financial management, fundraising, corporate governance and legal
- Multiple successful exits
- Executed over 10 IPOs




Luis Vasquez, Fraction Investor Relations

- Deep relationship with 100+ VCs
- Advised hundreds of start-ups on fundraising strategy and tactics
- Previously UCI Cove and Octane LaunchPad


SAB and advisors




Peter Tessier, PhD
Univ. Of Michigan
Leader in AI antibody design



Therapeutic expert



Pharma executive



AI leader

Interdisciplinary Talents



Biology



AI



Therapeutics



Microfluidics & Imaging




Data



BD & Operation


20 FTEs

Pharmaceutical industry model **has been broken for decades**




- Traditional drug discovery uses “trial and error”.
- Success is unpredictable, relying heavily on luck and chance.

AI-driven therapeutic design



We envision a future where therapeutic discovery and development are digitalized and democratized.

The language of life: Complex structure and function of proteins emerge from a sequence of amino acids



The data challenge


Data is Diamonds

*"The era of vast improvements in structure generation using open-access data repositories seems to be **coming to an end**. Proprietary data generation will be key to unlocking the next 10x improvement in ML for molecules."*

An Opinionated AlphaFold3 Field Guide, Dimension Research 2024


Aureka's generalizable foundation model for protein therapeutic design

Exponentially mimic, accelerate and explore 500 million years of co-evolution to decode the language of life



High-throughput evolution experiments -> data -> AI learns pattern -> decode molecular design principle -> design medicines on demand at scale

Aureka's differentiation: Antibody discovery technological evolution



Aureka Bio's value proposition



Accelerate
approval time

First-in-class



Better,
differentiable
candidates

Best-in-class



Optimal
quality

Clinical and commercial success



Unlock difficult
targets & new
MOAs


New markets

Aureka's high-value, scalable pipeline

Program	Target	Modality	Discovery	Pre-clinical POC	IND ready	Phase 1	Clinical POC	Partner
Metabolic								
Promiscuous receptor	Undisclosed	Dual targeting antibody						
Immunology & Inflammation								
Cytokine receptor agonists	Undisclosed	BsAB						 Pharma #1
Cytokine receptor antagonists	Undisclosed	mAb						
Cytokine antagonists	Undisclosed	BsAB						
Cytokine antagonists	Undisclosed	mAb						 Pharma #2
Oncology								
Efficient internalizing ADC	Undisclosed	Biparatopic ADC						 Venture #1

Aureka's model uniquely integrates value (BIC) and scalability (5X)


Asymmetric Value and Pricing:
Unmet needs that can only be addressed by Aureka (Best-in-class)



Traditional biotech (6-8 year to out-license), \$30-50 million cost


Aureka (2 years to out-license), \$5-8 million cost

Our scalability enables asymmetric investment return.




Our competitive differentiation strategy

Strong and growing IP portfolio, trade secrets and publication records



A

End-to-end integration




B

Proprietary data




C

Therapeutic assets



Aureka's value creation roadmap

Robust revenue in the short term with expansive value creation in the long term





Aureka Biotechnologies

Inspire therapeutic design

Dr. Weian Zhao, CEO
weianzhao@aurek.bio
aurek.bio